Short answer
OMEROS CORP (OMER) filed its Q3 2025 10-Q quarterly report on Nov 13, 2025 for the quarter ended Sep 30, 2025.
Q3 2025 key financials · XBRL
- Net income
- −$31M
- +4.1% YoY · −21.6% QoQ
- EPS (diluted)
- −$0.46
- +16.4% YoY · −7.0% QoQ
Source: XBRL data from the OMEROS CORP (OMER) Q3 2025 10-Q on SEC EDGAR. USD.
OMEROS CORP Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue not disclosed in provided MD&A; no quarterly YoY comparison available
- Research and development expenses $16.0M vs $24.1M YoY; direct external expenses $5.3M vs $12.2M
- Clinical R&D largest program: OMS906 $2.2M vs $5.3M YoY; OMS1029 and other lowest at $0.1M vs $1.2M
- Cash, equivalents and short-term investments $36.1M; nine-month operating cash use $76.3M
- Novo Nordisk transaction expected Q4 2025; $240.0M upfront cash, with $67.1M Term Loan repayment expected
Risk Factors
- New risk: Novo Nordisk transaction may fail to close, triggered by the APLA and pending HSR Act clearance
- Transaction delay threatens $240.0 million upfront payment and expected $2.1 billion total consideration
- Liquidity risk: without upfront proceeds, insufficient cash to repay Credit Agreement obligations and $17.1 million 2026 Notes
- Going-concern risk: failed closing could impair Credit Agreement covenant compliance and narsoplimab launch plans
- Operational risk: transaction uncertainty may disrupt personnel and vendor relationships and divert management attention
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other OMEROS CORP quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.